Home › Companies › Pharmaceuticals and biotechnology › United States
Is Bespoke Extracts, Inc. (BSPK) stock halal?
Thresholds exceeded under all standards, and the strict view excludes it.
This verdict follows the median view, that of AAOIFI Standard No. 21. It is based on the financial statements for the fiscal year ended 12/31/2024.
The ratios
| Criterion | Measure | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 62.5% of market capitalization | 30% | threshold exceeded |
| Interest-bearing investments | 12.5% of market capitalization | 30% | within threshold |
| Impermissible income | not published | 5% | to be verified |
Standard: AAOIFI, Standard No. 21.
Margin to threshold and trend
| Item | Ratio (fiscal year end) | Threshold (AAOIFI, Standard No. 21) | Margin | Change since year end | Estimated ratio |
|---|---|---|---|---|---|
| Interest-bearing debt | 62.5% | 30% | −32.5% | not read | — |
| Interest-bearing investments | 12.5% | 30% | 17.5% | not read | — |
Change read from the quarterly financial statements filed with the SEC (form 10-Q ended 09/30/2025, 3 quarters after fiscal year end), with the same reader on both dates. The estimated ratio applies this change to the annual ratio, with market capitalization unchanged: it is an estimate, not a verdict. "On watch" flags a permitted company whose estimated ratio reaches the threshold, or is within 5 points of the threshold and rising. This is neither a forecast nor advice.
The three views
- Median view, our reference : the company is excluded.
- Strictest view : the company is excluded, because it borrows or invests at interest.
- Most lenient view : the company is excluded.
Business activity
Pharmaceutical Preparations (SIC code 2834)
Financial statements read
Fiscal year ended 12/31/2024, in millions of dollars. Source: SEC EDGAR: annual reports of Bespoke Extracts, Inc..
What could not be verified
- Interest received: amount not isolated in the filed financial statements.
- Activity classified from the SEC sector code, without reading the annual report.
- Figures read automatically and not reviewed by a human.
Status history
Loading history…
In the same sector
- ELI LILLY & Co Questionable
- JOHNSON & JOHNSON Permitted
- AbbVie Inc. Permitted
- Merck & Co., Inc. Permitted
- AMGEN INC Prohibited
- GILEAD SCIENCES, INC. Permitted
- ABBOTT LABORATORIES Permitted
- PFIZER INC Questionable
Compliance comparison only: no opinion on the value of these securities.
General information: neither investment advice nor a fatwa. Verdict calculated by published rules, from financial statements read automatically and not reviewed by a human. Read the methodology